<DOC>
	<DOC>NCT02734446</DOC>
	<brief_summary>The purpose of this project is to evaluate in a randomized clinical trial, double-blind, controlled, the effects of a dietary supplement containing Lactobacillus reuteri DSM 17938 and vitamin D3 in reducing bronchial inflammation and improve asthma control in patients in children with mild / moderate persistent asthma .</brief_summary>
	<brief_title>To Evaluate the Efficacy of Supplementation With L. Reuteri + Vit. D3 in Asthmatic Children</brief_title>
	<detailed_description>To evaluate if the supplementation for three months with Lactobacillus reuteri DSM 17938 (108 CFU) + Vitamin D3 (400 IU) result in a reduction of the degree of allergic bronchial inflammation, measured with the Fractional exhaled nitric oxide (FeNO) and with a series of markers of bronchial inflammation (measured at 'beginning and at the end of the treatment on exhaled condensate): Interleukin 2(IL-2); Interleukin 4 (IL-4); Interleukin 10(IL-10); Interferon γ (IFN-γ).</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Patients aged between 6 and 14 years old, of both sexes Diagnosis of mild / moderate persistent asthma (GINA step 2/3) Allergy mite (Dermatophagoides farinae and pteronyssinus + + + / + + + +) Levels of vitamin 25 (OH) D &lt;30 ng / ml Signature of the informed consent of one parent or a legal representative Cardiovascular disease or systemic anatomical abnormalities Other respiratory diseases Taking probiotics and / or prebiotics in the previous 2 weeks Taking vitamin D or systemic corticosteroids within 4 weeks Participation in other clinical trials</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Bronchial Inflammation</keyword>
	<keyword>Asthma</keyword>
	<keyword>Childhood Asthma Control Test (C-ACT)</keyword>
	<keyword>Asthma Exacerbations</keyword>
</DOC>